The efficacy of bevacizumab plus paclitaxel as first-line treatment for HER2-negative metastatic breast cancer: a meta-analysis of randomized controlled trials.
about
AGO Recommendations for the Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2015.Efficacy and safety of adding an agent to bevacizumab/taxane regimens for the first-line treatment of Her2-negative patients with locally recurrent or metastatic breast cancer: results from seven randomized controlled trials.The efficacy and safety of bevacizumab combined with chemotherapy in treatment of HER2-negative metastatic breast cancer: a meta-analysis based on published phase III trials.
P2860
The efficacy of bevacizumab plus paclitaxel as first-line treatment for HER2-negative metastatic breast cancer: a meta-analysis of randomized controlled trials.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
The efficacy of bevacizumab pl ...... randomized controlled trials.
@en
The efficacy of bevacizumab pl ...... randomized controlled trials.
@nl
type
label
The efficacy of bevacizumab pl ...... randomized controlled trials.
@en
The efficacy of bevacizumab pl ...... randomized controlled trials.
@nl
prefLabel
The efficacy of bevacizumab pl ...... randomized controlled trials.
@en
The efficacy of bevacizumab pl ...... randomized controlled trials.
@nl
P2093
P2860
P1433
P1476
The efficacy of bevacizumab pl ...... randomized controlled trials.
@en
P2093
P2860
P2888
P304
P356
10.1007/S13277-014-1635-4
P577
2014-02-26T00:00:00Z